Umbilical cord blood mononuclear cells for inflammation-related diseases: a narrative review of immunomodulatory mechanisms, clinical evidence, and translational perspectives

Dysregulated inflammation contributes to both acute organ injury and chronic degenerative disease. Umbilical cord blood mononuclear cells (UCB-MNCs) constitute a heterogeneous cord-blood-derived cell product characterized by relative immune immaturity, potentially lower alloreactivity, and a higher proportion of naïve regulatory T-cell phenotypes than adult peripheral blood. UCB-MNCs have therefore been investigated as a candidate immunomodulatory cell therapy, but a critical cross-organ synthesis of their proposed mechanisms and clinical evidence remains limited. This narrative review critically integrates preclinical and clinical evidence on UCB-MNCs across neurological, cardiovascular, hepatic, renal, and pulmonary inflammation-related diseases. The clinical literature comprised 29 published reports involving approximately 1358 participants, of whom about 944 received UCB-MNC-containing interventions. These reports suggest generally acceptable short-term tolerability, but clinical efficacy remains uncertain because most studies were small, uncontrolled, methodologically limited, and clinically heterogeneous. Across preclinical studies, the most recurrent findings were predominantly associative and included immune-state-related marker changes, context-dependent adaptive immune regulation, and selective cytokine-network remodeling. Single-study perturbation or rescue experiments provided Grade B support for contributory IL-22–STAT3 signaling in acute liver injury, Nrf2-dependent autophagy and mitochondrial protection in septic acute kidney injury, Hedgehog-associated neurogenesis in neonatal brain injury, and CD40/CD40L-dependent amyloid-β clearance. Grade C evidence was limited to single-report associations involving neurotrophic factors, blood–brain barrier-related readouts, renal antifibrotic changes, and bronchopulmonary-dysplasia-associated alveolar–vascular remodeling. No mechanism met Grade A. Heterogeneity in cell-product definition, dose metrics, administration routes, treatment timing, and clinical endpoints remains a major translational barrier. Immunomodulation represents the most recurrent candidate mechanism of UCB-MNC-associated benefit, accompanied by context-dependent tissue-protective responses. Independent causal replication, standardized product characterization, disease- and mechanism-informed clinical trial design, and harmonized outcome reporting are required before clinical efficacy or optimal dosing can be established.